Search hospitals > Manitoba > WINNIPEG

Health Sciences Centre

Claim this profile
WINNIPEG, Manitoba R3A 1R9
Global Leader in Peroneal Nerve Injury
Global Leader in Crohn's Disease
Conducts research for Kidney Disorders
Conducts research for Sepsis
Conducts research for Infections and Infestations
141 reported clinical trials
20 medical researchers
Photo of Health Sciences Centre in WINNIPEGPhoto of Health Sciences Centre in WINNIPEGPhoto of Health Sciences Centre in WINNIPEG

Summary

Health Sciences Centre is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Peroneal Nerve Injury, Crohn's Disease, Kidney Disorders, Sepsis, Infections and Infestations and other specialties. Health Sciences Centre is involved with conducting 141 clinical trials across 468 conditions. There are 20 research doctors associated with this hospital, such as Sarvesh Logsetty, MD, Jai Shankar, MD FRCPC, Ryan Zarychanski, MD, and Tanya Sala, MD.

Top PIs

Clinical Trials running at Health Sciences Centre

Stroke
Spinal Cord Injury
Deep Partial Thickness Burn
Chronic Kidney Disease
Postoperative Pain
Limited Mobility
Burns
Ulcerative Colitis
Kidney Disorders
Human Papillomavirus
Image of trial facility.

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Recruiting3 awards Phase 44 criteria
Image of trial facility.

NoNO-42

for Stroke

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
Recruiting1 award Phase 23 criteria
Image of trial facility.

DECT

for Stroke

The goal of this clinical trial is to investigate the use of DECT (Dual-Energy Computed Tomography) in patients with acute ischemic stroke who receive an intervention (thrombolysis or thrombectomy). The main questions to answer are: 1. Can DECT more accurately differentiate hyperdensities as intracranial haemorrhage (ICH) or contrast extravasation compared with single-energy CT (SECT)?. 2. Will DECT lead to better care for patients with AIS who receive intervention and have post-procedural hyperdensities? Patients who receive intervention for acute ischemic stroke (AIS) receive a SECT at 24 hours as standard of care to determine if ICH is present. In the current study, a DECT will be done in addition to the SECT. Followup imaging (SECT or MRI) will be done at 72 hours to determine if the hyperdensity was indeed ICH. The accuracy of DECT for differentiating ICH from contrast extravasation will be compared.
Recruiting1 award N/A1 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Health Sciences Centre?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security